News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celator Pharmaceuticals, Inc. Announces Presentations of Positive Survival Analyses from CPX-351 Studies at American Society of Clinical Oncology Annual Meeting


6/5/2012 10:40:07 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive survival analyses from two completed clinical trials of CPX-351 (cytarabine:daunorubicin) Liposome Injection in acute myeloid leukemia (AML). A subset analysis of data from a randomized Phase 2b study in AML patients in first-relapse showed that patients with an unfavorable risk profile had significantly improved survival after treatment with CPX-351 compared to standard salvage therapies (ASCO Abstract 6525). Results from a second randomized Phase 2b study in elderly patients with newly diagnosed AML suggested that survival in patients with CRi (complete response with incomplete recovery of neutrophils or platelets) was similar to CR (complete response with complete recovery of neutrophils and platelets) (ASCO Abstract 6601), an effect usually not seen with standard treatment. The clinical findings were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES